Author

Cullen L. Myers

VenatoRx Pharmaceuticals (United States)ORCID 0000-0002-5789-2260Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:E. coli· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Annie StevensoniD· 2 shared Brittany Miller· 2 shared Daniel C. Pevear· 2 shared Denis M. DaigleiD· 2 shared Tsuyoshi UeharaiD· 2 shared Allison L. Zulli· 1 shared Ann E. JerseiD· 1 shared Anthony S. Drager· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Annie StevensonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A new class of penicillin-binding protein inhibitors to address drug-resistant Neisseria gonorrhoeae

Tsuyoshi Uehara, Allison L. Zulli, Brittany Miller, Lindsay M. Avery, Steven A. Boyd, Cassandra L. Chatwin, Guo‐Hua Chu, Anthony S. Drager, Mitchell Edwards, Susan G. Emeigh Hart, Nathan J. Line, Cullen L. Myers, Gopinath Rongala, Annie Stevenson, Kyoko Uehara, , Stephen M. Condon

This paper identifies a novel benzoxaborinine-based inhibitor (VNRX-14079) that effectively targets penA-mediated resistance in multidrug-resistant Neisseria gonorrhoeae.

Nature Microbiology · Apr 8, 2026Peer-reviewedMicrobiology

Cefepime-Taniborbactam and Ceftibuten-Ledaborbactam Maintain Activity Against KPC Variants that Lead to Ceftazidime-Avibactam Resistance

Cullen L. Myers, Annie Stevenson, Brittany Miller, Denis M. Daigle, Tsuyoshi Uehara, Daniel C. Pevear

This study evaluates the effectiveness of cefepime-taniborbactam and ceftibuten-ledaborbactam against KPC variants that confer resistance to ceftazidime-avibactam.

Antimicrobial Agents and Chemotherapy · Feb 10, 2025Peer-reviewedBiochemistry